Results 81 to 90 of about 1,338,841 (294)
Background The choice of cost data sources is crucial, because it influences the results of cost studies, decisions of hospital managers and ultimately national directives of policy makers.
Abdelbaste Hrifach +9 more
doaj +1 more source
Establishing cost-effectiveness of genetic targeting of cancer therapies [PDF]
The clinical benefit of a new genomic instrument, the 70-gene signature for breast cancer patients, is being evaluated in a randomised clinical trial. The early, controlled implementation process is supported by a Constructive Technology Assessment to ...
Harten, W.H. van +3 more
core +1 more source
Cost-effectiveness of managing Natura 2000 sites: an exploratory study for Finland, Germany, the Netherlands and Poland [PDF]
Natura 2000 sites are expected to assure the long-term survival of Europe's most valuable and threatened species and habitats. It follows that successful management of the sites is of great importance.
Apeldoorn, R.C., van +6 more
core +2 more sources
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz +15 more
wiley +1 more source
Background National and international policy makers have been increasing their focus on developing strategies to enable poor countries achieve the millennium development goals.
Evans David B +2 more
doaj +1 more source
The noncoding region of the genome plays a key role in regulating gene expression, and mutations within these regions are capable of altering it. Researchers have identified multiple functional noncoding mutations associated with increased cancer risk in the genome of breast cancer patients.
Arnau Cuy Saqués +3 more
wiley +1 more source
Participant Bidding Enhances Cost Effectiveness [PDF]
A multitude of design decisions influence the performance of voluntary conservation programs. This Economic Brief is one of a set of five exploring the implications of decisions policymakers and program managers must make about who is eligible to receive
Johansson, Robert C.
core +1 more source
Cost-effectiveness acceptability curves in the dock: case not proven? [PDF]
No abstract ...
Briggs, A.H., Fenwick, E.
core +2 more sources
We developed and validated a DNA methylation–based biomarker panel to distinguish pleural mesothelioma from other pleural conditions. Using the IMPRESS technology, we translated this panel into a clinically applicable assay. The resulting two classifier models demonstrated excellent performance, achieving high AUC values and strong diagnostic accuracy.
Janah Vandenhoeck +12 more
wiley +1 more source
Background In many countries, economic assessments of the routine use of pulse oximetry in the detection of Critical Congenital Heart Disease (CCHD) at birth has not yet been carried out.
Dario Londoño Trujillo +11 more
doaj +1 more source

